LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

Search

ADMA Biologics Inc

Closed

Sector Healthcare

10.97 2.33

Overview

Share price change

24h

Current

Min

10.75

Max

10.98

Key metrics

By Trading Economics

Income

35M

18M

Sales

8M

82M

EPS

0.08

Profit margin

21.748

Employees

624

EBITDA

7.9M

24M

Dividends

By Dow Jones

Next Earnings

7 sie 2024

Market Stats

By TradingEconomics

Market Cap

266M

2.4B

Previous open

8.64

Previous close

10.97

News Sentiment

By Acuity

50%

50%

92 / 369 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

ADMA Biologics Inc Chart

Related News

21 cze 2024, 17:53 UTC

Major Market Movers

Shares of Four U.S. Banks Slide as Regulator Finds Living Wills Weaknesses

23 cze 2024, 18:46 UTC

Acquisitions, Mergers, Takeovers

UPS Sells Freight Brokerage Operation to RXO -- WSJ

23 cze 2024, 11:00 UTC

Top News

The Rise of Chinese EVs Is Dividing the West -- Heard on the Street -- WSJ

23 cze 2024, 09:30 UTC

Top News

Apple, Meta Have Discussed an AI Partnership -- WSJ

22 cze 2024, 10:00 UTC

Top News

Nvidia Is No Cisco, but It Is Getting Expensive -- Heard on the Street -- WSJ

22 cze 2024, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

21 cze 2024, 23:45 UTC

Acquisitions, Mergers, Takeovers

Nvidia Is Surging. Why That's a Problem for a Tech ETF. -- Barrons.com

21 cze 2024, 22:19 UTC

Top News

Jury Convicts Milken Protégé Terren Peizer of Insider Trading -- WSJ

21 cze 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

21 cze 2024, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 cze 2024, 20:37 UTC

Top News

S&P 500 Clinches Third Straight Weekly Gain -- WSJ

21 cze 2024, 20:08 UTC

Top News

Apple Says Regulatory Concerns Might Prevent Rollout of AI Features in Europe -- Update

21 cze 2024, 19:22 UTC

Market Talk

Oil Futures Post Weekly Gain on Demand Expectations -- Market Talk

21 cze 2024, 19:04 UTC

Market Talk

Higher Output, Easing Heat Pressure U.S. Natural Gas -- Market Talk

21 cze 2024, 18:53 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Home Depot to Benefit from Diversified Consumer Base After Latest Acquisition -- Market Talk

21 cze 2024, 18:41 UTC

Market Talk

Gold Slides in Cautious Market -- Market Talk

21 cze 2024, 18:41 UTC

Market Talk

Global Equities Roundup: Market Talk

21 cze 2024, 18:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 cze 2024, 18:34 UTC

Market Talk

Mexico's Peso Gets Lift From Picks for New Cabinet -- Market Talk

21 cze 2024, 17:53 UTC

Earnings

Delta Stock Is a Winner. Its CEO Explains Why It Can Fly Higher. -- Barrons.com

21 cze 2024, 17:43 UTC

Market Talk

U.S. Oil Rig Count Falls to 485 -- Market Talk

21 cze 2024, 17:32 UTC

Top News

Apple Says Regulatory Concerns May Prevent Rollout of AI Features in Europe -- WSJ

21 cze 2024, 17:16 UTC

Acquisitions, Mergers, Takeovers

Penn Could be Getting a Buyout Offer. Wall Street Doesn't Agree on What It Means for the Stock. -- Barrons.com

21 cze 2024, 17:06 UTC

Top News

Regulators Cite Big Banks, Including Goldman Sachs and JPMorgan, Over Living Wills -- WSJ

21 cze 2024, 16:29 UTC

Market Talk

Strong USD a Pressure Point for Grains -- Market Talk

21 cze 2024, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 cze 2024, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

21 cze 2024, 15:46 UTC

Market Talk

Gold Futures Slump as Strong U.S. Business Activity Boosts Dollar -- Market Talk

21 cze 2024, 15:40 UTC

Market Talk

Citi Sees Chance of Sustained Oil Price Rally -- Market Talk

21 cze 2024, 15:30 UTC

Market Talk

Canadian Core Retail Sales Rebound in April Seen as Encouraging -- Market Talk

Peer Comparison

Price change

ADMA Biologics Inc Forecast

Rating Consensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

10.47 / N/ASupport & Resistance

Short Term

Bearish Evidence

Intermediate Term

No Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

92 / 369 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About ADMA Biologics Inc

ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include ADMA BioManufacturing and Plasma Collection Centers. The Company’s ADMA BioManufacturing segment reflects its immune globulin manufacturing and development operations in Florida. The Plasma Collection Centers segment consists of approximately three plasma collection facilities. Its products include BIVIGAM, ASCENIV and Nabi-HB. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons.